Current Clinical Trials | Lung Research Florida

Breakthrough 2025 Clinical Trials

Access the most advanced respiratory treatments available through our cutting-edge research studies featuring revolutionary 2025 medical breakthroughs. All investigational medications and study-related care provided at no cost to participants.

🔬 Ultra-Long-Acting Biologics

🧬 Dual-Pathway Targeting

🎯 Neurological Cough Control

11 Active 2025 Studies

$0 Cost to Participants

100% Study-Related Care Covered

Ultra-Long-Acting Dual-Pathway Biologic for Severe Asthma

Now Enrolling Severe Asthma 2025 Breakthrough

Revolutionary ultra-long-acting biologic requiring only two injections per year. This groundbreaking therapy simultaneously targets IL-4/IL-13 and IL-5 inflammatory pathways, representing the future of severe asthma treatment with unprecedented convenience and efficacy.

Study Overview

This landmark study investigates the world's first ultra-long-acting biologic treatment that requires dosing only every 6 months. Unlike traditional biologics requiring monthly injections, this revolutionary therapy provides continuous protection against severe asthma with just two annual treatments. The innovative dual-pathway mechanism simultaneously blocks both Type 2 inflammation and eosinophilic pathways, potentially offering superior asthma control and dramatically improved quality of life.

2025 Medical Breakthrough Features

6-Month Dosing: Revolutionary ultra-long-acting formulation requiring only 2 injections per year
Dual-Pathway Targeting: First-in-class simultaneous IL-4/IL-13 and IL-5 inhibition
Enhanced Binding Affinity: Advanced molecular engineering for superior efficacy
Complete Protection: Continuous coverage against all asthma exacerbation triggers
Oral Steroid Elimination: Potential to completely discontinue systemic corticosteroids

Am I Eligible?

You May Qualify If You:

Are 18-75 years old
Have physician-diagnosed severe asthma for at least 12 months
Are taking high-dose inhaled corticosteroids plus additional controller for at least 3 months
Have had 2 or more asthma exacerbations in the past year requiring oral steroids
Have elevated Type 2 biomarkers (blood eosinophils ≥300 cells/μL OR FeNO ≥50 ppb)
Score ≥1.5 on Asthma Control Questionnaire despite optimal therapy
Are seeking reduced injection frequency and improved convenience

You May NOT Qualify If You:

Are currently pregnant or breastfeeding
Have active smoking within past 6 months
Have received any biologic therapy within 5 months
Have significant cardiovascular, liver, or kidney disease
Have active parasitic infection or immunodeficiency disorders
Have contraindications to long-acting biologics

Study Facts

Duration: 52 weeks + long-term follow-up

Visits: Only 8 visits (vs 15+ for monthly biologics)

Treatment: Subcutaneous injection every 6 months

Compensation: Up to $2,500 for completed participation

Participation Benefits

Free ultra-long-acting biologic medication (value >$50,000/year)
Dramatically reduced clinic visit requirements
Advanced biomarker assessment and monitoring
Comprehensive pulmonary function testing
Quality of life evaluations and specialist care
Potential for oral steroid elimination
Priority access to breakthrough 2025 therapies

Check Your Eligibility Call to Learn More

Advanced P2X3 Receptor Neurological Cough Treatment

Now Enrolling Chronic Cough 2025 Breakthrough

Revolutionary neurological approach targeting P2X3 receptors with enhanced selectivity and reduced side effects. This breakthrough treatment represents the future of chronic cough management for patients who have exhausted all conventional therapies.

Study Overview

This cutting-edge study investigates the most advanced P2X3 receptor antagonist available in 2025, featuring unprecedented selectivity for P2X3 versus P2X2/3 receptors. This enhanced selectivity dramatically reduces taste disturbances while maintaining superior cough suppression. The treatment targets the neurological hypersensitivity that underlies refractory chronic cough, offering hope for patients who have failed all conventional treatments.

2025 Neurological Breakthrough

Enhanced Selectivity: 20-fold selectivity for P2X3 vs P2X2/3 reduces side effects
Optimal Dosing: Advanced pharmacokinetics for maximum efficacy
Rapid Response: Cough frequency reduction within 2-4 weeks
Quality of Life: Restoration of normal daily activities and sleep
Neuroplasticity: Potential for long-lasting cough pathway normalization

Am I Eligible?

You May Qualify If You:

Are 18-80 years old
Have chronic refractory cough for 1+ years
Rate your cough severity as moderate to severe (≥40mm on VAS)
Have failed all standard treatments (ACE inhibitors, PPIs, antihistamines)
Have normal chest imaging within past year
Are non-smoker or quit smoking >6 months ago
Have documented cough frequency >10 coughs/hour

You May NOT Qualify If You:

Have active respiratory infection or illness
Are current smoker or quit within 6 months
Have significant lung disease causing the cough
Are taking medications known to cause cough
Have baseline taste or smell disorders
Are pregnant, breastfeeding, or planning pregnancy

Study Facts

Duration: 12 weeks treatment + 12 weeks follow-up

Visits: 7 visits over 6 months

Treatment: Oral medication twice daily

Compensation: Up to $1,200 for completed participation

Participation Benefits

Free advanced P2X3 receptor antagonist medication
24-hour objective cough frequency monitoring
Validated cough severity and quality of life assessments
Comprehensive taste and smell testing
Neurological cough reflex evaluation
Access to breakthrough 2025 cough treatments
Long-term follow-up and support

Check Your Eligibility Call to Learn More

THARROS: Triple vs Dual Therapy for Cardiac Events in COPD

Now Enrolling COPD Cardiac Protection

Groundbreaking Phase 3/4 study comparing triple inhaled therapy versus dual therapy for reducing heart attacks and strokes in COPD patients. This landmark trial could redefine cardiovascular protection strategies for COPD management.

Study Overview

This pivotal study investigates whether adding an inhaled corticosteroid to dual bronchodilator therapy can significantly reduce major cardiovascular events (heart attacks and strokes) in COPD patients at high cardiac risk. This represents a paradigm shift in COPD treatment, focusing not just on respiratory symptoms but on comprehensive cardiovascular protection.

Groundbreaking Cardiac Protection Features

Cardiovascular Focus: First major trial primarily targeting cardiac events in COPD
Comprehensive Protection: Evaluating reduction in heart attacks and strokes
Inflammation Control: Anti-inflammatory approach to systemic COPD effects
Risk Stratification: Focus on high cardiovascular risk patients
Long-term Outcomes: Extended follow-up for major cardiac events

Am I Eligible?

You May Qualify If You:

Are 40-80 years old
Have confirmed COPD diagnosis (FEV1/FVC ratio < 70%)
Have smoking history ≥10 pack-years
Have blood eosinophils ≥100 cells/mm³
Have CAT score ≥10 with phlegm and cough items ≥2 each
Have cardiovascular risk factors (prior heart attack, stents, or 3+ risk factors)
Have not used inhaled corticosteroids >2 months in past year

You May NOT Qualify If You:

Have asthma diagnosis
Are on long-term inhaled corticosteroids
Have severe liver or kidney disease
Have unstable cardiovascular conditions
Cannot use MDI devices properly
Have contraindications to study medications

Study Facts

Duration: Up to 4 years follow-up

Visits: Every 3-6 months

Treatment: Triple or dual inhaled therapy

Primary Focus: Heart attack and stroke prevention

Participation Benefits

Free triple or dual combination inhaler therapy
Comprehensive cardiovascular monitoring
Regular cardiac biomarker testing
Advanced lung function assessments
Cardiovascular risk evaluation
Close monitoring by specialists
Contribution to landmark cardiac protection research

Check Your Eligibility Call Research Line

AIRLYMPUS: Novel Subcutaneous Treatment for High-Risk Asthma

Now Enrolling High-Risk Asthma Pre-Biologic Innovation

Revolutionary subcutaneous injection therapy for high-risk asthma patients not yet eligible for traditional biologics. This innovative treatment bridges the gap between standard therapy and biologic eligibility, offering advanced control for difficult-to-treat asthma.

Study Overview

This 52-week Phase 2 study investigates a novel subcutaneous treatment specifically designed for high-risk asthma patients on medium-dose inhaled therapy who don't yet qualify for traditional biologics. This innovative approach targets inflammatory pathways earlier in the disease process, potentially preventing progression to severe asthma requiring more intensive treatments.

Innovative Pre-Biologic Features

Early Intervention: Targets inflammation before severe asthma develops
Subcutaneous Delivery: Convenient injection therapy
Exacerbation Prevention: Focus on reducing asthma attacks
Lung Function Improvement: Enhanced FEV1 outcomes
Bridge Therapy: Fills gap between standard care and biologics

Am I Eligible?

You May Qualify If You:

Are 18-80 years old
Have asthma on medium-dose inhaled corticosteroids with LABA
Had at least 1 asthma exacerbation in past year
Have blood eosinophils >300 cells/μL at screening
Have FeNO >50 ppb at screening
Show reversibility on spirometry or have documented history
Are not currently eligible for biologic treatment

You May NOT Qualify If You:

Had respiratory infection within 4 weeks
Used anti-IgE therapy within 130 days
Used other biologics within 2 months or 5 half-lives
Are using LAMA in addition to ICS/LABA
Have significant other medical conditions
Are pregnant or planning pregnancy

Study Facts

Duration: 52 weeks

Visits: Monthly visits

Treatment: Subcutaneous injection

Design: Randomized, double-blind, placebo-controlled

Participation Benefits

Free investigational subcutaneous therapy
Regular monitoring of asthma control
Advanced biomarker testing
Comprehensive lung function assessments
Early access to innovative pre-biologic treatment
Close specialist monitoring
Compensation for time and travel

Check Your Eligibility Call Research Line

CALM2: Advanced P2X3 Inhibitor for Refractory/Neuropathic Cough

Now Enrolling Chronic Cough Neuropathic Treatment

Next-generation P2X3 receptor inhibitor specifically designed for chronic refractory or neuropathic cough. This advanced therapy offers hope for patients with persistent cough lasting over one year who have not responded to conventional treatments.

Study Overview

The CALM2 study evaluates an innovative P2X3 inhibitor for patients with chronic refractory or unexplained chronic cough. This targeted therapy addresses the neurological hypersensitivity underlying persistent cough, particularly in cases where standard treatments for underlying conditions have failed to provide relief.

Advanced Neuropathic Cough Treatment

Targeted Mechanism: Selective P2X3 receptor antagonism
Long-term Relief: Designed for persistent cough lasting >1 year
Refractory Focus: For patients who've exhausted other options
Quality Improvement: Reduces cough severity and frequency
Safety Profile: Optimized to minimize taste disturbances

Am I Eligible?

You May Qualify If You:

Are 18-80 years old
Have persistent cough for ≥1 year prior to screening
Have refractory or unexplained chronic cough diagnosis
Have cough severity VAS ≥40 mm at screening
Have chest imaging within 5 years showing no significant abnormality
Meet eligibility adjudicator confirmation criteria
Can use appropriate contraception if required

You May NOT Qualify If You:

Are current smoker or quit <6 months ago
Have >20 pack-year smoking history
Have COPD, bronchiectasis, or pulmonary fibrosis
Have uncontrolled asthma
Have incomplete workup for reflux or rhinitis
Have other significant respiratory disorders

Study Facts

Duration: Variable based on protocol

Visits: Regular monitoring visits

Treatment: Oral P2X3 inhibitor

Focus: Refractory/neuropathic cough

Participation Benefits

Free advanced P2X3 inhibitor medication
Comprehensive cough assessment
Cough severity monitoring
Quality of life evaluations
Expert specialist care
Access to breakthrough therapy
Compensation for participation

Check Your Eligibility Call Research Line

IMAGINE: Ultra-Long-Acting IL-5 Therapy with Advanced CT Imaging

Now Enrolling Severe Asthma 6-Month Dosing

Revolutionary IL-5 antagonist requiring only two doses per year, combined with advanced CT imaging to visualize lung improvements. This groundbreaking study offers no placebo group - all participants receive active treatment.

Study Overview

The IMAGINE study is a 52-week Phase 3b trial evaluating an ultra-long-acting IL-5 antagonist administered just twice yearly. Uniquely, this study uses high-resolution CT scanning to document structural lung improvements over time. With no placebo group, all participants receive active treatment, making this an exceptional opportunity for severe asthma patients.

Revolutionary IL-5 Treatment Features

Ultra-Long-Acting: Only 2 doses per year (every 26 weeks)
No Placebo: All participants receive active treatment
CT Imaging: Visualize lung improvements over time
Eosinophil Control: Targets eosinophilic inflammation
Bronchoscopy Option: Optional substudy with lung sampling

Am I Eligible?

You May Qualify If You:

Are 18 years or older
Have blood eosinophils >300 cells/μL
Had ≥2 asthma exacerbations in past year
Have FeNO >25 ppb at screening
On medium/high-dose ICS >12 months plus controller
Can undergo CT scanning (no metal implants)
Optional: willing to undergo bronchoscopy

You May NOT Qualify If You:

Received anti-IL-5 therapy within 12 months
Failed previous anti-IL-5/5R therapy
Used other biologics within 12 months
Had exacerbation within 6 weeks
Have pacemaker or metal prosthesis
Used investigational drugs recently

Study Facts

Duration: 52 weeks

Visits: Every 3-6 months

Treatment: SC injection every 26 weeks

Special: HRCT imaging included

Participation Benefits

Guaranteed active treatment (no placebo)
Ultra-convenient 6-month dosing
Advanced HRCT lung imaging
Comprehensive biomarker testing
Optional bronchoscopy substudy
See your lung improvements on CT
Expert asthma specialist care

Check Your Eligibility Call Research Line

NAZARE: Novel Anti-TSLP Antibody with 6-Month Dosing

Now Enrolling Asthma Exacerbations Ultra-Long-Acting

Breakthrough anti-TSLP antibody requiring dosing only every 6 months. This innovative treatment differs from existing TSLP therapies with enhanced pharmacokinetics and ultra-long duration of action.

Study Overview

The NAZARE study is a 52-week Phase 2 trial investigating a novel anti-TSLP antibody with revolutionary 6-month dosing intervals. This treatment targets the TSLP pathway differently than existing therapies, offering sustained control of both eosinophilic and non-eosinophilic inflammation. Patients are stratified by FeNO levels to optimize treatment response.

Next-Generation TSLP Inhibition

6-Month Dosing: Revolutionary convenience with biannual injections
Dual Inflammation Control: Effective for all asthma phenotypes
FeNO Stratification: Personalized based on inflammation type
Exacerbation Prevention: Focus on reducing asthma attacks
Biomarker Monitoring: Track FeNO and eosinophil changes

Am I Eligible?

You May Qualify If You:

Are 18-75 years old
Have asthma diagnosis >2 years
Had ≥1 exacerbation in past 12 months
On medium/high-dose ICS plus controller
Show reversibility or have documented history
Any FeNO level (stratified <25 or ≥25 ppb)
Willing to adjust current medications

You May NOT Qualify If You:

Used biologics within 4 months or 5 half-lives
Recent systemic steroids (within 15 days)
Active respiratory infection
Significant cardiovascular disease
History of anaphylaxis
Pregnant or planning pregnancy

Study Facts

Duration: 52 weeks

Visits: Monthly initially, then quarterly

Treatment: SC injection every 6 months

Design: Randomized, placebo-controlled

Participation Benefits

Ultra-long-acting anti-TSLP therapy
Only 2 injections per year
Personalized FeNO-based treatment
Regular lung function testing
Comprehensive symptom monitoring
ACQ-5 quality of life assessments
Expert asthma care

Check Your Eligibility Call Research Line

Novel Nanobody Dual IL-13/TSLP Inhibition for COPD

Now Enrolling COPD Exacerbations Dual-Target Nanobody

Revolutionary nanobody technology simultaneously targeting IL-13 and TSLP pathways in COPD. This first-in-class therapy addresses both inflammatory pathways with a single molecule for superior exacerbation prevention.

Study Overview

This Phase 2b/3 study investigates an innovative nanobody that uniquely targets both IL-13 and TSLP inflammatory pathways. Designed for moderate to very severe COPD patients with frequent exacerbations, this dual-action approach represents a paradigm shift in COPD management by addressing multiple inflammatory mechanisms simultaneously.

Breakthrough Nanobody Technology

Dual Inhibition: Simultaneous IL-13 and TSLP blockade
Nanobody Design: Enhanced tissue penetration and stability
Exacerbation Focus: For high-risk COPD patients
Eosinophilic COPD: Particularly effective for elevated eosinophils
Triple Therapy Compatible: Works with existing treatments

Am I Eligible?

You May Qualify If You:

Are 40-80 years old
Have moderate to very severe COPD (≥12 months)
Post-bronchodilator FEV1 ≥20% and ≤70% predicted
Smoking history ≥10 pack-years
CAT score ≥10
≥2 moderate or ≥1 severe exacerbation in past year
On triple therapy (LABA+LAMA+ICS) ≥3 months
Blood eosinophils ≥150 cells/μL

You May NOT Qualify If You:

Have asthma diagnosis
Have other significant lung diseases
Require oxygen >4.0 L/min
Recent COPD exacerbation (within 4 weeks)
Recent MI, TIA, or stroke (<6 months)
Heart failure NYHA Class III/IV

Study Facts

Duration: 48 weeks treatment

Visits: Monthly monitoring

Treatment: Subcutaneous nanobody

Focus: Exacerbation reduction

Participation Benefits

Free innovative nanobody therapy
Dual-pathway inflammation control
Regular lung function monitoring
SGRQ quality of life assessments
Comprehensive COPD management
Biomarker monitoring
Expert pulmonologist care

Check Your Eligibility Call Research Line

PRESTO: Revolutionary IRAK4 Inhibitor for COPD Inflammation

Now Enrolling COPD Novel Mechanism

First-in-class IRAK4 pathway inhibitor targeting chronic inflammation in COPD through toll-like receptors and IL-1 family pathways. This breakthrough oral therapy offers a completely new approach to reducing COPD exacerbations.

Study Overview

The PRESTO study investigates a revolutionary IRAK4 inhibitor that blocks key inflammatory signals in COPD. By targeting toll-like receptors and IL-1 family pathways, this oral medication addresses the underlying chronic inflammation that drives COPD progression and exacerbations. This represents an entirely new therapeutic approach for COPD management.

Novel IRAK4 Pathway Inhibition

New Mechanism: First IRAK4 inhibitor for COPD
Oral Therapy: Convenient tablet formulation
Inflammation Control: Targets TLR and IL-1 pathways
Exacerbation Prevention: Reduces inflammatory triggers
Disease Modification: Potential to slow progression

Am I Eligible?

You May Qualify If You:

Are ≥40 years old
Have moderate to very severe COPD ≥12 months
On stable triple or dual therapy ≥3 months
≥2 moderate or ≥1 severe exacerbation in past year
Documentation of exacerbations available
Willing to continue background therapy
Can provide informed consent

You May NOT Qualify If You:

Have asthma or other lung diseases
Have unstable cardiovascular disease
Recent MI (<6 months)
Have active tuberculosis
Have HIV or hepatitis B/C
Significant liver/kidney dysfunction

Study Facts

Duration: Variable per protocol

Visits: Regular monitoring

Treatment: Oral IRAK4 inhibitor

Innovation: First-in-class for COPD

Participation Benefits

Access to novel IRAK4 inhibitor
Convenient oral medication
Comprehensive inflammation monitoring
Regular safety assessments
Exacerbation tracking
Potential disease modification
Expert COPD management

Check Your Eligibility Call Research Line

Phase 1B IL-33 Antibody Safety Study in COPD

Now Enrolling COPD $150/visit

Early-phase study evaluating a novel IL-33 antibody for COPD patients. This 52-week safety study offers substantial compensation while exploring a new inflammatory pathway in COPD treatment.

Study Overview

This Phase 1B study investigates the safety and tolerability of an IL-33 antibody in COPD patients. IL-33 is an alarmin cytokine that plays a crucial role in COPD inflammation and exacerbations. This study represents an early exploration of IL-33 inhibition as a potential new treatment approach for COPD.

IL-33 Pathway Innovation

Novel Target: IL-33 alarmin cytokine inhibition
Safety Focus: Comprehensive safety monitoring
Compensation: $150 per study visit
Long Duration: 52-week commitment
Eosinophilic COPD: For patients with elevated eosinophils

Am I Eligible?

You May Qualify If You:

Are 40-75 years old
Body weight 50-110 kg, BMI 19.5-32
Confirmed COPD >12 months
FEV1/FVC <0.70 and FEV1 ≥40% predicted
On stable COPD therapy 3+ months
Blood eosinophils ≥150 cells/μL
Former/current smoker ≥10 pack years
SARS-CoV-2 vaccinated (2 doses + booster)

You May NOT Qualify If You:

History of significant medical conditions
MI within 12 months
Pneumonia within 3 months
Current asthma diagnosis
Pulmonary fibrosis or bronchiectasis
Atrial fibrillation
Chronic immunosuppressive use
Positive TB, hepatitis, or HIV

Study Facts

Duration: 52 weeks

Compensation: $150 per visit

Treatment: IL-33 antibody

Phase: 1B safety study

Participation Benefits

$150 compensation per visit
Access to novel IL-33 therapy
Comprehensive safety monitoring
Regular health assessments
Contribute to early research
Close medical supervision
Help advance COPD treatment

Check Your Eligibility Call Research Line

ENDURA: IL-5 Inhibition for Eosinophilic COPD Exacerbators

Now Enrolling Eosinophilic COPD Precision Medicine

Targeted IL-5 antagonist therapy specifically for COPD patients with Type 2 inflammation and elevated eosinophils. This precision medicine approach identifies the subset of COPD patients most likely to benefit from anti-eosinophilic treatment.

Study Overview

The ENDURA study evaluates IL-5 inhibition in carefully selected COPD patients with eosinophilic inflammation. This represents a precision medicine approach to COPD, targeting treatment to patients with specific inflammatory phenotypes who are most likely to respond. The study focuses on frequent exacerbators with elevated eosinophils.

Precision COPD Treatment

Targeted Therapy: For eosinophilic COPD only
IL-5 Inhibition: Reduces eosinophilic inflammation
Exacerbation Focus: For frequent exacerbators
Biomarker-Driven: Eosinophil and Type 2 markers
Personalized Approach: Precision medicine for COPD

Am I Eligible?

You May Qualify If You:

Have COPD with frequent exacerbations
Elevated blood eosinophils
Evidence of Type 2 inflammation
On optimal COPD therapy
History of ≥2 exacerbations yearly
Willing to continue background therapy
Meet biomarker criteria

You May NOT Qualify If You:

Primary asthma diagnosis
Low eosinophil counts
Recent biologic therapy
Active parasitic infection
Immunodeficiency disorders
Unable to use study medications

Study Facts

Duration: Per protocol

Treatment: IL-5 antagonist

Focus: Eosinophilic COPD

Approach: Precision medicine

Participation Benefits

Targeted IL-5 therapy
Precision medicine approach
Regular eosinophil monitoring
Comprehensive COPD care
Biomarker assessments
Exacerbation prevention focus
Expert specialist management

Check Your Eligibility Call Research Line

Referring Physicians: Access 2025 Medical Breakthroughs

Lung Research Florida offers your patients exclusive access to the most advanced respiratory treatments available in 2025, including ultra-long-acting biologics, P2X3 receptor antagonists, and precision medicine approaches not available anywhere else in South Florida.

🔬 Cutting-Edge 2025 Therapies

Ultra-long-acting biologics requiring only 2 injections yearly, revolutionary neurological cough treatments, and precision medicine for complex cases

📊 Comprehensive Reporting

Detailed progress reports, biomarker analysis, and treatment outcomes shared with referring physicians throughout study participation

⚡ Fast-Track Enrollment

Same-day physician referral processing with eligibility assessment typically completed within 48 hours

View Physician Resources Call Research Referral Line

Interested in Revolutionary 2025 Treatments?

Our specialized research coordinators are available to discuss these breakthrough studies and determine eligibility for these cutting-edge therapies. All consultations are free, confidential, and available in English and Spanish.

Research Enrollment

954-522-7226 x1

Monday - Friday: 8:00 AM - 6:00 PM
Saturday: 9:00 AM - 2:00 PM

Email Research Team

inquire@lungresearchflorida.com

Response within 4 hours during business days

Visit Our Research Center

Lung Research Florida
Research Facility of Advanced Asthma Clinic
10059 NW 1st Court
Plantation, FL 33324